ライフサイエンスコーパス: tuberculosis

1 loped incident TBI without subsequent active tuberculosis).

2 n are at increased risk of developing active tuberculosis.

3 an immunodeficiency virus (HIV), malaria and tuberculosis.

4 ding of drug susceptibility to Mycobacterium tuberculosis.

5 shift in the microenvironment during primary tuberculosis.

6 erculosis cases and matched controls without tuberculosis.

7 ssed in adults with HIV and drug-susceptible tuberculosis.

8 rculosis complex (MTC), a causative agent of tuberculosis.

9 with additional risk factors for developing tuberculosis.

10 re were no radiologic features suggestive of tuberculosis.

11 nd BCG vaccination on the risk of developing tuberculosis.

12 lesions of mice infected with Mycobacterium tuberculosis.

13 pes of latent infection and active pulmonary tuberculosis.

14 the host-pathogen interface of Mycobacterium tuberculosis.

15 to an index patient with multidrug-resistant tuberculosis.

16 repertoire of epoxide hydrolase genes in M. tuberculosis.

17 ower prevalence of LTBI in adult contacts of tuberculosis.

18 tion with different strains of Mycobacterium tuberculosis.

19 trated activity against multi-drug-resistant tuberculosis.

20 pyrazinamide susceptibility in Mycobacterium tuberculosis.

21 One hundred forty-eight had culture-positive tuberculosis, 100 had community-acquired pneumonia (CAP)

22 ve investment ($772 per DALY), compared with tuberculosis ($156 per DALY), malaria ($125 per DALY), a

23 ibrosing mediastinitis (1%), and pericardial tuberculosis (2%).

24 cobalamin has been linked to pathogenesis of tuberculosis(2).

25 g all children <5 years of age who developed tuberculosis, 83% were diagnosed within 90 days of the b

26 persistent pathogens, such as Mycobacterium tuberculosis, actively target the very host pathways act

27 show that the AHAS complex of Mycobacterium tuberculosis adopts a similar structure, thus demonstrat

28 Genetic diversity of Mycobacterium tuberculosis affects immune responses and clinical outco

29 012, we identified 4,500 index patients with tuberculosis and 14,044 tuberculosis-exposed household c

30 f a correlate(s) of protection against human tuberculosis and a validated animal model of the disease

31 imal signature for short-term risk of active tuberculosis and evaluated its predictive value in indep

32 In Mycobacteria tuberculosis and Francisella tularensis, biotin biosynth

33 he intracerebral inflammatory response to M. tuberculosis and improve TBM clinical outcomes.

34 e the inflammatory response to Mycobacterium tuberculosis and influence disease presentation and outc

35 Mycobacterium tuberculosis and M. smegmatis form drug-tolerant biofilm

36 HIV, tuberculosis infection status, previous tuberculosis); and (2) estimating the effectiveness of p

37 In high-burden settings, deaths due to HIV, tuberculosis, and malaria over 5 years could increase by

38 ck microbiological evidence of Mycobacterium tuberculosis, and misdiagnosis or delayed diagnosis ofte

39 g herpesviruses, retroviruses, Mycobacterium tuberculosis, and Toxoplasma gondii.

40 niae, and unspecified pneumonia); influenza; tuberculosis; and other lower and upper respiratory infe

41 total IgA, and IgA specific to Mycobacterium tuberculosis antigen in the exhaled breath samples, obta

42 The reconstitution of Mycobacterium tuberculosis antigen-specific CD4 T cells in a cohort of

43 Tuberculosis-associated IRIS was uncommon (4/arm), with

44 s Streptococcus pneumoniae and Mycobacterium tuberculosis AtaC is monomeric in solution and binds Mn(

45 Diagnosis of active tuberculosis (ATB) currently relies on detection of Myco

46 ordering of the N terminus of Mycobacterium tuberculosis ATR, which organizes a dynamic cobalamin bi

47 n in morphological features of Mycobacterium tuberculosis bacilli to develop a rapid profiling platfo

48 it was first used in humans as a vaccine for tuberculosis, Bacillus Calmette-Guerin (BCG) has been su

49 king cessation is important in patients with tuberculosis because it can reduce the high rates of tre

50 By contrast, screening for latent tuberculosis before immune checkpoint inhibitor treatmen

51 ovis (the causative agent of bovine/zoonotic tuberculosis, bTB) infection.

52 biosynthesis of coenzyme A in Mycobacterium tuberculosis by binding to aspartate decarboxylase PanD.

53 esting that they may confer advantages to M. tuberculosis by modulating its interactions with host ce

54 aims: (1) estimating the risk of developing tuberculosis by time-period of follow-up, demographics (

55 vo efficacy of polyclonal IgG against the M. tuberculosis capsular polysaccharide arabinomannan (AM).

56 uberculosis in children closely exposed to a tuberculosis case and followed for incident disease.

57 t-TST-only approach led to 13 fewer incident tuberculosis cases (IQR -5 to -18) and four additional s

58 ala, Uganda, to delineate social networks of tuberculosis cases and matched controls without tubercul

59 tacts would probably reduce the incidence of tuberculosis cases in high-burden settings.

60 onal analysis of data from adult contacts of tuberculosis cases participating in a UK cohort study.

61 Sixteen pediatric Indian tuberculosis cases were age- and sex-matched to 32 tuber

62 , a treat-all approach led to fewer incident tuberculosis cases, and additional adverse events increa

63 The Mycobacterium tuberculosis cell envelope is a critical interface betwe

64 Deletion of PPE51 rendered M. tuberculosis cells unable to replicate on propionamide,

65 ogenicity and protective efficacy against M. tuberculosis challenge.

66 ve previously demonstrated that Mycobacteria tuberculosis chaperonin 60.1 inhibits leucocyte diapedes

67 Tuberculosis claims more human lives than any other bact

68 DNA adenine methylomes for 93 Mycobacterium tuberculosis complex (MTBC) isolates from seven lineages

69 of drug-resistance profile of Mycobacterium tuberculosis complex (MTC), a causative agent of tubercu

70 In a new UK cohort of 333 HIV-negative tuberculosis contacts with a median follow-up of 346 day

71 ciency virus (HIV)-negative UK cohort of 333 tuberculosis contacts.

72 stratification of short-term disease risk in tuberculosis contacts.

73 t this risk reflects incipient disease among tuberculosis contacts.

74 findings contribute to our understanding of tuberculosis control and have implications for the devel

75 fect of P2C/5-OP-RU-induced MAIT cells on M. tuberculosis control.

76 We analyzed Mycobacterium tuberculosis culture-positive cases reported to the Nati

77 only play a role in phagosome rupture and M. tuberculosis cytosolic translocation but also function a

78 survival of phagocytosed M. smegmatis or M. tuberculosis D. discoideum cells lacking the putative po

79 pression profiling is emerging as a tool for tuberculosis diagnosis and treatment response monitoring

80 Improved tuberculosis diagnostics and tools for monitoring treatm

81 Although rare, subclinical tuberculosis disease can be missed during evaluations fo

82 preventive therapy had a lower incidence of tuberculosis disease even when they had been exposed to

83 Tuberculosis disease is a major global public health con

84 was associated with increased risk of active tuberculosis disease up to 10 years before diagnosis.

85 at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and a

86 e between magnitude of HCMV IgG with risk of tuberculosis disease.

87 ependently associated with increased risk of tuberculosis disease.

88 ed for 1 year for the occurrence of incident tuberculosis disease.

89 e not associated with differences in odds of tuberculosis disease.

90 Tuberculosis disproportionately affects the Canadian Inu

91 ent regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeutic options, re

92 erial cell envelope, and are targets of anti-tuberculosis drug ethambutol.

93 ery in hospitalized adult patients with anti-tuberculosis drug induced liver injury (AT-DILI).

94 Thus, the old tuberculosis drug pyrazinamide exerts antibacterial acti

95 Pyrazinamide is a sterilizing first-line tuberculosis drug.

96 ulmonary pharmacokinetics of first-line anti-tuberculosis drugs.

97 sm of the cell wall and surface lipids in M. tuberculosis during growth and stasis, and speculate abo

98 Due to their role in detoxification, M. tuberculosis EH's have been identified as potential drug

99 ing antiretroviral treatment (ART) in a high tuberculosis endemic area is described.

100 lineages are responsible for globally-spread tuberculosis epidemics, whereas TbD1-intact "ancestral"

101 38 years old UK-born White adults with first tuberculosis episode, and randomly selected age and sex

102 is crucial for survival and virulence of M. tuberculosis ESAT-6, a 6-kDa-secreted protein of region

103 important virulence factors of Mycobacterium tuberculosis, EsxA and EsxB not only play a role in phag

104 ulosis cases were age- and sex-matched to 32 tuberculosis-exposed controls (13 developed incident TBI

105 index patients with tuberculosis and 14,044 tuberculosis-exposed household contacts who we followed

106 Lower protection from BCG with increasing M. tuberculosis exposure and age can inform vaccine develop

107 d for the discovery of a novel class of anti-tuberculosis F-ATP synthase inhibitors.

108 terial pathogens that includes Mycobacterium tuberculosis, generates a salicyl-capped peptide mycobac

109 l typically yielded higher mean depths of M. tuberculosis genome coverage, with an overall range of 0

110 ons of children are exposed to Mycobacterium tuberculosis globally every year; however, there are no

111 tilis GyrB, which exceeds the activity of M. tuberculosis gyrase and reaches the activity of the B. s

112 is study, the limit of detection (LOD) of M. tuberculosis H37Rv in all spiked animal samples were 2 C

113 DMs) were infected with laboratory strain M. tuberculosis H37Rv or clinical isolates from various lin

114 The recent rise of drug-resistant tuberculosis has complicated the choice of treatment reg

115 Unlike most other organisms M. tuberculosis has six putative genes for epoxide hydrolas

116 expanded in other chronic infections such as tuberculosis, hepatitis B and C, and HIV, as well as in

117 orm treatment strategies in patients with M. tuberculosis/HIV coinfection.

118 ion on the persistent forms of Mycobacterium tuberculosis However, no drug susceptibility test (DST)

119 library against intracellular Mycobacterium tuberculosis identified 1, a thioalkylbenzoxazole hit.

120 uss new approaches that will help dissect M. tuberculosis immune evasion mechanisms and devise strate

121 rch attention as a possible manifestation of tuberculosis immune reconstitution inflammatory syndrome

122 ationale: A human model to better understand tuberculosis immunopathogenesis and facilitate vaccine d

123 These data inform the study of tuberculosis immunopathogenesis and strategies for evalu

124 nostic methods for identifying Mycobacterium tuberculosis in cerebrospinal fluid (CSF) are inadequate

125 analysis, we investigated the development of tuberculosis in children closely exposed to a tuberculos

126 emporary estimates of the risk of developing tuberculosis in exposed children.

127 ial role in virulence and pathogenesis of M. tuberculosis In our earlier study, we demonstrated that

128 ins in regulating macrophage responses to M. tuberculosis In this study, we demonstrate that TRIM14,

129 pulmonary delivery daily over 10 days to M. tuberculosis infected mice for FG2 HSA nanoparticles (0.

130 om 74 individuals presumed to have latent M. tuberculosis infection (LTBI) based on close contact wit

131 uberculosis (Mtb) during asymptomatic latent tuberculosis infection (LTBI) in humans is currently lac

132 flammatory responses used to identify latent tuberculosis infection (LTBI) lose positivity during pre

133 SIV adults, 14.4% were diagnosed with latent tuberculosis infection (LTBI), 63.5% were susceptible to

134 ata specific to Indian children and incident tuberculosis infection (TBI) exist.

135 Variation in the outcome of tuberculosis infection and diseases has been attributed

136 nce that suggests BCG may protect against M. tuberculosis infection as well as disease.

137 h M tuberculosis or reactivation of latent M tuberculosis infection during such treatment.

138 nd previously reported genes associated with tuberculosis infection in a cohort with longitudinal mea

139 e associated with decreased prevalence of M. tuberculosis infection in adults.

140 arly innate immune response to Mycobacterium tuberculosis infection in the lung.

141 (age, region), and clinical attributes (HIV, tuberculosis infection status, previous tuberculosis); a

142 nd exacerbate pathology during Mycobacterium tuberculosis infection upon GM-CSF blockade.

143 can be missed during evaluations for latent tuberculosis infection, and can manifest with symptoms d

144 tes (T2D) have a lower risk of Mycobacterium tuberculosis infection, progression from infection to tu

145 rom 97 US immigrants at various stages of M. tuberculosis infection, we showed protective in vitro an

146 ving type I IFN responses and controlling M. tuberculosis infection.

147 alize IL-10 in cynomolgus macaques during M. tuberculosis infection.

148 bacterial burden and disease pathology in M. tuberculosis infection.

149 .15]) among those with a positive result for tuberculosis infection.

150 d the choice of treatment regimen for latent tuberculosis infection.Objectives: To evaluate the effec

151 n this review, we focus on how Mycobacterium tuberculosis infects antigen-presenting cells and evades

152 th confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis treatment between 1

153 Because Mycobacterium tuberculosis is an activator of cGAS-dependent cytosolic

154 n mycolic acid biosynthesis in Mycobacterium tuberculosis is catalysed by mycolyl reductase encoded b

155 g prevalence of drug-resistant Mycobacterium tuberculosis is making disease control more difficult.

156 CCs) for categorizing clinical Mycobacterium tuberculosis isolates as susceptible/resistant to the dr

157 pically characterized clinical Mycobacterium tuberculosis isolates.

158 lum that includes the pathogen Mycobacterium tuberculosis, lack the canonical FtsZ-membrane anchors a

159 Mycobacterium tuberculosis (M. tb.) is a pervasive respiratory disease

160 hen a person was infected with Mycobacterium tuberculosis (M.tb) is critical as recent infection is t

161 24-week guinea pig vaccination-Mycobacterium tuberculosis (M.tb.) challenge model to test the protect

162 Blood transcriptional biomarkers of tuberculosis may predate clinical diagnosis, suggesting

163 We assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts

164 PZA resistance in multidrug-resistant tuberculosis (MDR-TB) is common and it is not clear how

165 d a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to

166 Data included ART use and anti-tuberculosis medications grouped according to WHO effect

167 ontacts of patients with multidrug-resistant tuberculosis.Methods: In a prospective cohort study cond

168 nce of rapid tests to identify Mycobacterium tuberculosis (MTB) and detect isoniazid (INH) and rifamp

169 ectious diseases, is caused by Mycobacterium tuberculosis (MTB) and remains a public health problem n

170 viduals latently infected with Mycobacterium tuberculosis (Mtb) and to group them according to their

171 Mycobacterium tuberculosis (Mtb) continues to be a major health threat

172 eficiency resulted in improved Mycobacterium tuberculosis (Mtb) control during chronic but not acute

173 ct evidence for persistence of Mycobacterium tuberculosis (Mtb) during asymptomatic latent tuberculos

174 Mycobacterium tuberculosis (Mtb) employs plethora of mechanisms to hij

175 ille Calmette-Guerin (BCG) and Mycobacterium tuberculosis (MTB) Erdman.

176 for tuberculosis (TB) are the Mycobacterium tuberculosis (Mtb) escape from phagolysosomal destructio

177 Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb) infection and is a major public healt

178 Strategies to prevent Mycobacterium tuberculosis (Mtb) infection are urgently required.

179 Mycobacterium tuberculosis (Mtb) infection is among top ten causes of

180 Ag85A expressed by Mycobacterium tuberculosis (Mtb) is a bacterial surface protein that i

181 Mycobacterium tuberculosis (Mtb) is the leading cause of death from in

182 epA that are found in clinical Mycobacterium tuberculosis (Mtb) isolates phenocopy lepA deletion to v

183 Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) latently infects approximately one-fo

184 Mycobacterium tuberculosis (Mtb) strains are classified into different

185 e presentation of ligands from Mycobacterium tuberculosis (Mtb) to MAIT cells.

186 's population is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis

187 ivity are globally elevated in Mycobacterium tuberculosis (Mtb)-infected macrophages.

188 Ruhl et al. find that a Mycobacterium tuberculosis (Mtb)-specific lipid, SL-1, stimulates huma

189 hich is caused by the pathogen Mycobacterium tuberculosis (Mtb).

190 resistant clinical isolates of Mycobacterium tuberculosis (Mtb).

191 sly replicating populations of Mycobacterium tuberculosis (Mtb).

192 rrently relies on detection of Mycobacterium tuberculosis (Mtb).

193 s demonstrated potent efficacy in an in vivo tuberculosis murine infection model.

194 data from clinical trials and literature on tuberculosis natural history to model outcomes, assuming

195 The new Global Tuberculosis Network (GTN) aims to conduct research on k

196 tive multicenter study within the Paediatric Tuberculosis Network European Trials Group, capturing pa

197 In the second independent study, tuberculosis occurred in none of the 76 household contac

198 Tuberculosis odds were four times higher in subjects wit

199 ub-Saharan Africa and the effects of HIV and tuberculosis on COVID-19 outcomes are unknown.

200 umber of reports of primary infection with M tuberculosis or reactivation of latent M tuberculosis in

201 onserved in the orthologous proteins from M. tuberculosis Our findings support a role for EspE and Es

202 n and type I IFN production, key features of tuberculosis pathogenesis.

203 from a total of 208 isolates recovered from tuberculosis patients in Bamako, Mali between 2006 and 2

204 which the accuracy of detection of positive tuberculosis patients was estimated.

205 samples, obtained from healthy subjects and tuberculosis patients.

206 e, we used this technology to evaluate if M. tuberculosis peptides can also be detected in individual

207 pectrometry (MRM-MS) assays that detected M. tuberculosis peptides in serum extracellular vesicles fr

208 There were no IEps due to Mycobacterium tuberculosis, Pneumocystis jirovecii, or Toxoplasma gond

209 Final validation employed M. tuberculosis-positive clinical samples (n = 20), reveali

210 Mycobacterium tuberculosis possesses a large number of genes of unknow

211 Additionally, tuberculosis presents with notable clinical heterogeneit

212 fectivity and suggests the use of statins as tuberculosis preventive therapy by inhibiting PDIM sprea

213 These studies suggest that M. tuberculosis probably targets the ESAT-6 protein to incr

214 M. tuberculosis produces two classes of siderophore, lipid-

215 elome) of Salmonella enterica, Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Staphylococcus

216 Pulmonary tuberculosis (PTB) is one of the major health problems i

217 Clinically diagnosed pulmonary tuberculosis (PTB) patients lack microbiological evidenc

218 lture-confirmed, drug-susceptible, pulmonary tuberculosis receiving standard 4-drug therapy (isoniazi

219 f patients with RMA after ATT may experience tuberculosis relapse within 6 mo of completing ATT.

220 The major causes of deaths were AIDS- or tuberculosis-related conditions both within 42 days of d

221 ication of the deadly pathogen Mycobacterium tuberculosis relies on the production of small organic m

222 tly better than control cells at limiting M. tuberculosis replication.

223 Unlike macrophages, where M. tuberculosis resides in early-phagosomal compartments, i

224 targeted deletion of the pe/ppe genes in M. tuberculosis resulted in enhanced autophagy and improved

225 The Mg(2+)-dependent Mycobacterium tuberculosis salicylate synthase (MbtI) is a key enzyme

226 smission network inferred from Mycobacterium tuberculosis sequencing data on extensively drug-resista

227 iography) to determine whether treatment for tuberculosis should be started or to receive systematic

228 We hypothesized that M. tuberculosis-specific inflammatory responses used to ide

229 iative organized by the Collaborative Ocular Tuberculosis Study (COTS), along with the International

230 The Collaborative Ocular Tuberculosis Study (COTS), supported by the Internationa

231 African participants with varying degrees of tuberculosis susceptibility.

232 hogenicity precluded in vivo studies, the M. tuberculosis Tam also replaced E. coli BioC both in vivo

233 criptions and also promoted MDSC research in tuberculosis (TB) and AIDS.

234 Infectious diseases like tuberculosis (TB) and HIV are especially difficult to ad

235 the DNA methylation status of patients with tuberculosis (TB) and their asymptomatic household conta

236 Pathogenesis hallmarks for tuberculosis (TB) are the Mycobacterium tuberculosis (Mt

237 We studied the mutational rates of 24 index tuberculosis (TB) cases and their latently infected hous

238 Tuberculosis (TB) claims 1.5 million lives per year.

239 Tuberculosis (TB) continues to claim the lives of around

240 Tuberculosis (TB) control is hindered by absence of rapi

241 tegies are needed for the early diagnosis of tuberculosis (TB) disease and treatment of latent TB inf

242 The risk of progression to tuberculosis (TB) disease is greatest soon after infecti

243 ined by cell surface markers, decline during tuberculosis (TB) disease, consistent with redistributio

244 sis infection, progression from infection to tuberculosis (TB) disease, TB morality and TB recurrence

245 Using CLEIMiT, we found that the anti-tuberculosis (TB) drug bedaquiline (BDQ) is localised no

246 Tuberculosis (TB) elimination requires innovative approa

247 nalysis of patients with isoniazid-resistant tuberculosis (TB) given standard first-line anti-TB trea

248 The diagnosis of tuberculosis (TB) in HIV-infected patients is challengin

249 rapy (IPT) is widely used to protect against tuberculosis (TB) in people living with human immunodefi

250 Tuberculosis (TB) incidence in India continues to be hig

251 Tuberculosis (TB) is a chronic infection that can affect

252 Tuberculosis (TB) is caused by Mycobacterium tuberculosi

253 Tuberculosis (TB) is the leading cause of death from a s

254 Tuberculosis (TB) is the leading cause of mortality and

255 Tuberculosis (TB) is the leading infectious cause of dea

256 Helminths and tuberculosis (TB) largely overlap at the population leve

257 ecrotic, nonnecrotic, and cavitary pulmonary tuberculosis (TB) lesions.

258 Patterns of transmission of drug-resistant tuberculosis (TB) remain poorly understood, despite over

259 Tuberculosis (TB) remains a major infectious disease wor

260 Diabetes mellitus (DM) increases tuberculosis (TB) risk.

261 Previously treated tuberculosis (TB) was documented in 2 patients.

262 testing for all patients being evaluated for tuberculosis (TB), a lack of rapid diagnostic tests whic

263 unodeficiency virus (HIV) who have pulmonary tuberculosis (TB), but its effects on the lungs have not

264 Tuberculosis (TB), caused by Mycobacterium tuberculosis

265 only screened for during the exam, including tuberculosis (TB), hepatitis B, hepatitis C, malaria, st

266 berculosis, the causative agent of pulmonary tuberculosis (TB), is responsible for millions of infect

267 Tuberculosis (TB), one of the deadliest infectious disea

268 apeutic used to treat the infectious disease tuberculosis (TB), which is caused by the pathogen Mycob

269 ts immune responses and clinical outcomes of tuberculosis (TB).

270 m tuberculosis (Mtb), the causative agent of tuberculosis (TB).

271 of novel concepts for improved management of tuberculosis (TB).

272 same-day microbiological testing for active tuberculosis (TB).

273 new opportunities for the early detection of tuberculosis (TB).

274 FujiLAM with Xpert for tuberculosis testing in hospitalized people with HIV is

275 Mycobacterium tuberculosis, the causative agent of pulmonary tuberculo

276 -established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided improved pharma

277 mg twice daily both during and 2 weeks after tuberculosis therapy, then 50 mg once daily) or efaviren

278 tomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicycli

279 outh Africa (Rapid urine-based Screening for Tuberculosis to reduce AIDS Related Mortality in hospita

280 Cough, a hallmark of tuberculosis, transmits the disease.

281 Participants on rifampicin-based tuberculosis treatment <=8 weeks were randomized (3:2) t

282 multidrug-resistant tuberculosis initiating tuberculosis treatment between 1993 and 2016.

283 rvention substantially increased coverage of tuberculosis treatment in this high-risk population, but

284 and HIV independently predicted unsuccessful tuberculosis treatment outcomes.

285 utol produced promising results for improved tuberculosis treatment outcomes.

286 de (PZA) is considered the pivot drug in all tuberculosis treatment regimens due to its particular ac

287 an antibiotic used in first- and second-line tuberculosis treatment regimens.

288 ned less weight during the first 2 months of tuberculosis treatment, and lack of weight gain and HIV

289 and can manifest with symptoms during latent tuberculosis treatment.

290 ive individuals during the first 2 months of tuberculosis treatment.

291 tly, mPTPB represents an exciting target for tuberculosis treatment.

292 toxicity and effectiveness of drugs used for tuberculosis treatment.

293 strategies for evaluation and development of tuberculosis vaccine candidates.

294 elopment of BCG-vectored STING agonists as a tuberculosis vaccine strategy.

295 The Mycobacterium tuberculosis virulence factor EsxA and its chaperone Esx

296 eness of preventive therapy against incident tuberculosis was estimated through propensity score matc

297 In a sample of 597 Indian patients with tuberculosis, we compared 99DOTS' adherence assessments

298 neonatal disorders, diarrhoeal diseases, and tuberculosis were the top five Level 3 causes of death.

299 tic amino acid biosynthesis in Mycobacterium tuberculosis, which shows extremely complex dynamic allo

300 d blood transcriptional biomarkers of active tuberculosis will improve stratification of short-term d